004080.KS
Shinhung Co., Ltd
KSC · Healthcare · Medical - Devices · KR
KRW 14,060.00
−0.21%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 105.9B | 102.6B | 101.8B | 112.4B | 118.2B |
| Cost of Revenue | 72.9B | 70.7B | 70.8B | 76.4B | 83.4B |
| Gross Profit | 33.0B | 31.9B | 30.9B | 36.0B | 34.8B |
| Operating Expenses | |||||
| R&D Expense | 855.0M | 917.8M | 682.8M | 830.5M | 743.7M |
| SG&A Expense | 16.9B | 10.0B | 9.9B | 10.3B | 10.1B |
| General & Admin Expense | 2.6B | 3.4B | 3.6B | 4.0B | 3.6B |
| Selling & Marketing Expense | 4.9B | 6.5B | 6.2B | 6.3B | 6.5B |
| Other Expenses | 10.8B | 14.0B | 14.1B | 13.6B | 13.5B |
| Total Operating Expenses | 24.4B | 24.9B | 24.6B | 24.7B | 24.3B |
| Cost and Expenses | 97.3B | 95.5B | 95.5B | 101.1B | 107.7B |
| Operating Income (EBIT) | 8.6B | 7.1B | 6.3B | 11.4B | 10.5B |
| Non-Operating | |||||
| Interest Income | 972.5M | 893.1M | 199.5M | 233.8M | 149.5M |
| Interest Expense | 1.2B | 1.4B | 455.5M | 427.7M | 407.4M |
| Net Interest Income | (212.0M) | (470.9M) | (256.0M) | (193.9M) | (257.9M) |
| Other Non-Op Income/Expense | (1.4B) | (2.2B) | 798.2M | 623.8M | (95.3M) |
| Non-Operating Income (excl Interest) | 1.7B | 1.7B | (1.3B) | (1.1B) | (312.1M) |
| EBT (Pre-Tax Income) | 7.2B | 4.9B | 7.1B | 12.0B | 10.4B |
| Income Tax Expense | 1.7B | 2.0B | 1.9B | 2.7B | 1.9B |
| Bottom Line | |||||
| Net Income | 5.4B | 2.8B | 5.2B | 9.2B | 8.5B |
| Earnings from Cont. Ops | 5.5B | 2.9B | 5.2B | 9.2B | 8.5B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 5.4B | 2.8B | 5.2B | 9.2B | 8.5B |
| Per Share | |||||
| Basic EPS | ₩593 | ₩311 | ₩552 | ₩980 | ₩901 |
| Diluted EPS | ₩593 | ₩311 | ₩552 | ₩980 | ₩901 |
| Revenue Per Share | ₩11,460 | ₩11,307 | ₩10,776 | ₩11,940 | ₩12,586 |
| Shares | |||||
| Basic Shares Outstanding | 9.2M | 9.1M | 9.4M | 9.4M | 9.4M |
| Diluted Shares Outstanding | 9.2M | 9.1M | 9.4M | 9.4M | 9.4M |
| Profitability Metrics | |||||
| EBITDA | 11.4B | 9.3B | 10.1B | 15.3B | 13.6B |
| D&A | 3.8B | 3.9B | 3.2B | 2.9B | 2.9B |
| EBIT | 8.6B | 5.4B | 6.9B | 12.4B | 10.8B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026